The New Political Economy of Pharmaceuticals
-14 %
Der Artikel wird am Ende des Bestellprozesses zum Download zur Verfügung gestellt.

The New Political Economy of Pharmaceuticals

Production, Innovation and TRIPS in the Global South
Sofort lieferbar | Lieferzeit:3-5 Tage I

Unser bisheriger Preis:ORGPRICE: 84,95 €

Jetzt 72,99 €*

Hans Löfgren
International Political Economy Series
eBook Typ:
eBook Format:
1 - PDF Watermark
1. The New Political Economy of Pharmaceuticals: Conformity and Resistance in the Global South; Owain David Williams and Hans Löfgren 2. The Political Economy of Pharmaceutical Production in Brazil; Cassandra M. Sweet 3. Pharmaceuticals, Health Policy and Intellectual Property Rights in China; Chee-Ruey Hsieh 4. Immunity to TRIPS? Vaccine Production and the Biotechnology Industry in Cuba; Jens Plahte and Simon Reid-Henry 5. TRIPS and Access to Medicines in Egypt; Dina Iskander 6. The Pharmaceutical Industry in India after TRIPS; Sudip Chaudhuri 7. The Health Care System and the Pharmaceutical Industry in Indonesia; Richard Husada and Raymond R. Tjandrawinata 8. TRIPS, Free Trade Agreements and the Pharmaceutical Industry in Malaysia; Mohamed Azmi Hassali, Jayabalan Thambyappa, Shankaran Nambiar and Asrul Akmal Shafie 9. The Pharmaceutical Industry, Intellectual Property Rights and Access to Medicines in Pakistan: Zaheer-Ud-Din Babar, Shazia Jamshed, Ashar Malik and Anwarul-Hassan Gilani 10. TRIPS, Access to Medicines and Local Production in South Africa; Andrew L. Gray and Yousuf A. Vawda 11. TRIPS and New Challenges for the Pharmaceutical Sector in South Korea; Bong-min Yang and Hye-young Kwon 12. Intellectual Property Rights and Neoliberal Restructuring in Turkey: The Pharmaceutical Industry; Ipek Eren Vural 13. Conclusion: TRIPS, Drug Production in the Global South, and Access to Medicines; Hans Löfgren and Owain David Williams
Some two decades will shortly have passed since the WTO's Trade Related Aspects of Intellectual Property Rights agreement came into force in 1995. This volume is the first cross-country analysis of how TRIPS has affected the capacity of 11 major low or medium income countries to produce generic drugs.

Kunden Rezensionen

Zu diesem Artikel ist noch keine Rezension vorhanden.
Helfen sie anderen Besuchern und verfassen Sie selbst eine Rezension.